Gilead Sciences, Inc. (NASDAQ:GILD) Director John Francis Cogan sold 2,413 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $75.27, for a total value of $181,626.51. Following the completion of the sale, the director now directly owns 57,273 shares of the company’s stock, valued at approximately $4,310,938.71. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

John Francis Cogan also recently made the following trade(s):

  • On Monday, March 16th, John Francis Cogan sold 2,413 shares of Gilead Sciences stock. The shares were sold at an average price of $67.26, for a total value of $162,298.38.
  • On Monday, March 9th, John Francis Cogan sold 2,413 shares of Gilead Sciences stock. The shares were sold at an average price of $77.97, for a total value of $188,141.61.

GILD traded up $2.00 during trading hours on Thursday, reaching $71.66. The company’s stock had a trading volume of 6,776,565 shares, compared to its average volume of 30,795,556. The company has a debt-to-equity ratio of 1.02, a quick ratio of 3.01 and a current ratio of 3.10. The firm has a market cap of $91.13 billion, a PE ratio of 17.02, a price-to-earnings-growth ratio of 5.79 and a beta of 0.99. The company’s 50-day moving average is $71.37 and its 200-day moving average is $66.57. Gilead Sciences, Inc. has a 52 week low of $60.89 and a 52 week high of $85.97.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, missing the consensus estimate of $1.67 by ($0.37). The firm had revenue of $5.88 billion for the quarter, compared to the consensus estimate of $5.74 billion. Gilead Sciences had a return on equity of 35.49% and a net margin of 23.99%. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.44 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 6.03 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a dividend of $0.68 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.63. The ex-dividend date of this dividend is Thursday, March 12th. This represents a $2.72 annualized dividend and a yield of 3.80%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.30%.

A number of hedge funds have recently bought and sold shares of GILD. TRUE Private Wealth Advisors bought a new position in shares of Gilead Sciences in the fourth quarter worth $25,000. Pin Oak Investment Advisors Inc. bought a new position in shares of Gilead Sciences in the fourth quarter worth $26,000. IndexIQ Advisors LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth $28,000. TFO TDC LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth $29,000. Finally, Tortoise Investment Management LLC increased its position in shares of Gilead Sciences by 922.2% in the fourth quarter. Tortoise Investment Management LLC now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 415 shares during the period. Hedge funds and other institutional investors own 80.32% of the company’s stock.

Several equities research analysts have recently commented on the company. Cowen reissued a “buy” rating and issued a $85.00 price objective on shares of Gilead Sciences in a report on Thursday, January 2nd. Raymond James downgraded Gilead Sciences from a “strong-buy” rating to an “outperform” rating and cut their price objective for the company from $81.00 to $80.00 in a report on Wednesday, February 5th. SunTrust Banks reissued a “hold” rating on shares of Gilead Sciences in a report on Wednesday. Royal Bank of Canada reissued a “buy” rating and issued a $83.00 price objective on shares of Gilead Sciences in a report on Wednesday. Finally, Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a report on Sunday, February 9th. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and fifteen have issued a buy rating to the stock. Gilead Sciences presently has an average rating of “Hold” and an average target price of $78.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: FinTech

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.